Literature DB >> 8168083

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

G N Thalmann1, P E Anezinis, S M Chang, H E Zhau, E E Kim, V L Hopwood, S Pathak, A C von Eschenbach, L W Chung.   

Abstract

Our laboratory has previously reported on the derivation of LNCaP cell sublines from LNCaP tumors maintained in castrated and intact athymic male mice. These LNCaP sublines differ from the parental line in tumorigenicity and androgen dependence. This paper demonstrates that one of these sublines acquired metastatic potential. When inoculated either s.c. or orthotopically, the C4-2 subline metastasized to the lymph node and bone with an incidence of 11-50%. Interestingly, the incidence of osseous metastasis was higher in castrated than in intact male hosts. We evaluated the chromosomal, immunohistochemical, and biochemical characteristics of the LNCaP sublines derived from C4-2 tumors that metastasized to the lymph node and bone. Cytogenetic analysis showed that all sublines were human and shared common marker chromosomes with the parental LNCaP cells. This experimental human prostate cancer model may permit, for the first time, the study of the molecular mechanisms underlying human prostate cancer metastasis.

Entities:  

Mesh:

Year:  1994        PMID: 8168083

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  296 in total

1.  Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.

Authors:  Shumin Zhang; Yanru Wang; Zhengjia Chen; Sungjin Kim; Shareen Iqbal; Andrew Chi; Chad Ritenour; Yongqiang A Wang; Omer Kucuk; Daqing Wu
Journal:  Prostate       Date:  2013-09-02       Impact factor: 4.104

2.  Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Authors:  Mehmet Asim Bilen; Marcella M Johnson; Paul Mathew; Lance C Pagliaro; John C Araujo; Ana Aparicio; Paul G Corn; Nizar M Tannir; Franklin C Wong; Michael J Fisch; Christopher J Logothetis; Shi-Ming Tu
Journal:  Cancer       Date:  2014-08-22       Impact factor: 6.860

3.  MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.

Authors:  Jingjing Li; Tianjie Pu; Lijuan Yin; Qinlong Li; Chun-Peng Liao; Boyang Jason Wu
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

4.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

5.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

6.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

7.  Parathyroid hormone-related protein regulates integrin α6 and β4 levels via transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V R Mula; Miriam Falzon
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

8.  Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.

Authors:  Lizheng Guo; Diansheng Zhong; Stephen Lau; Xiuju Liu; Xue-Yuan Dong; Xiaodong Sun; Vincent W Yang; Paula M Vertino; Carlos S Moreno; Vijay Varma; Jin-Tang Dong; Wei Zhou
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

Review 9.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

10.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.